Home » Topics » BioWorld Science

BioWorld Science
RSS

BioAegis cleared to begin phase II study of rhu-pGSN in severe COVID-19 pneumonia

July 16, 2020

Octapharma reports on use of Octagam IVIG in critically ill patients with COVID-19

July 16, 2020

RBM-007 enters phase I study for treatment of achondroplasia

July 16, 2020

FDA clears IND for clinical evaluation of long-acting human IL-7 NT-17 for mild COVID-19

July 16, 2020

CS-3003, an HDAC6 inhibitor, shows promise for treating multiple myeloma

July 16, 2020

Zydus begins human dosing with ZyCoV-D vaccine

July 16, 2020

Byondis initiates phase II study of SYD-985 in advanced endometrial cancer

July 16, 2020

Can-Fite amends phase II COVID-19 study protocol based on FDA guidance

July 16, 2020

Novocure and MSD to study Tumor Treating Fields with Keytruda in NSCLC

July 16, 2020

First child dosed in phase II study of infigratinib in achondroplasia

July 16, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...